Is the idea of getting a flu vaccine more fun if you know you can do it at home?
That'll be a real option as soon as next year, following the US Food and Drug Administration's recent approval of the first-ever flu vaccine for "self-administration."
The vaccine, called FluMist, is a nasal vaccine that's been available since 2003 but given in-clinic by a healthcare provider. It works by activating the immune system with a weakened form of live influenza virus and is approved for people ages 2 through 49.
While it's not expected to be rolled out in time for this year's flu season -- for which conventional vaccines are already available -- it marks a new step in reducing the risk of severe illness for a virus that causes between 100,000 and 710,000 hospitalizations and 4,900 to 51,000 deaths each year, according to an estimate from the US Centers for Disease Control and Prevention. For people who dislike needles or those who can't travel to get a vaccine, a self-given nasal vaccine is an important option.
Here's what to know about FluMist, the upcoming DIY flu vaccine.
How can I get the new at-home flu vaccine?
FluMist won't be available until next year, according to the website for FluMist, which is owned by AstraZeneca. Once it does become available, you'll still need a prescription.
According to the FDA, the nasal vaccine is expected to be available through a "third-party online pharmacy," making it not only a needle-free option, but one you can get shipped right to your door.
Who can get the at-home flu vaccine?
FluMist is only approved for kids age 2 and up and adults under age 50.
The reason for this may be due to the fact that the nasal vaccine contains a weakened)version of live virus, which may be less safe for people with weakened immune systems. In addition to age restrictions, the CDC has said those who are pregnant, people who are immunocompromised and those with other medical conditions should not get the nasal vaccine.
If you have a question about whether FluMist will be right for you, you'll go through a regular prescription and screening process when it becomes available.
"Regular" in-office injection vaccines, such as the ones available for the 2024-2025 virus season, will remain options.